Dementia news should report who was left out because a study's results directly describe only the people actually studied. Without that context, readers may wrongly assume a treatment or risk finding applies to every person with dementia. "Left out" includes people excluded by eligibility rules and groups represented by too few participants for reliable conclusions. Reporting those gaps helps families judge whether a headline fits their diagnosis, disease stage, health history, and background.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- A result applies to a defined population
- What the major drug trials actually studied
- Small groups create unanswered questions
- Exclusion reaches beyond race and ethnicity
- Questions readers can use
A result applies to a defined population
A clinical trial does not answer whether a treatment works for everyone. It tests a particular intervention in people who meet specific requirements, under controlled conditions.
Those requirements may include a diagnosis, disease stage, biomarker result, age range, medication history, or ability to complete scans and other procedures. Each rule narrows the population that the results directly describe. This distinction matters when news coverage turns "slowed decline in eligible participants" into "slows dementia." The broader wording erases both the trial's boundaries and the many forms and stages of dementia it did not examine.
What the major drug trials actually studied
Lecanemab's pivotal trial enrolled people with confirmed amyloid pathology and either mild cognitive impairment or mild dementia. It did not establish the same result for later-stage disease or other dementias, according to the FDA's lecanemab trial summary. Donanemab's pivotal trial was similarly selective.
Participants needed amyloid confirmation, tau-PET selection, mild cognitive impairment or mild dementia, and MMSE scores from 20 to 28, as detailed in the FDA's donanemab trial summary. MMSE is a brief test of memory and other thinking abilities. These studies can provide meaningful evidence for people who resemble their participants. They cannot, by themselves, show the same balance of benefit and risk for someone with advanced disease, a different dementia, or a different biomarker profile.
Small groups create unanswered questions
Enrollment totals can hide major gaps. In lecanemab's 1,795-person trial, 76.9% of participants were White and 2.6% were Black. The FDA said the small numbers of non-White participants prevented conclusions about racial differences in effectiveness. The disparity was larger in donanemab's 1,736-person trial: 91.5% of participants were White and 2.3% were Black.
Again, the FDA said effectiveness differences among racial groups could not be determined. That does not prove the drugs work differently across racial groups. It means the trials did not provide enough evidence to answer the question reliably. News reports should distinguish "no difference was found" from "the study could not determine whether a difference exists.".
Exclusion reaches beyond race and ethnicity
Strict enrollment rules can exclude people because of age, medicines, medical or psychiatric conditions, or unwillingness or inability to undergo required procedures. One estimate cited in the National Institute on Aging's recruitment strategy found that fewer than one-third of people with Alzheimer's would be eligible for trials. These exclusions may be necessary for safety or to answer a focused scientific question.
But they also create uncertainty for patients with several illnesses, complex medication regimens, limited mobility, or difficulty reaching specialist clinics. Study setting matters too. NIA-funded research comparing a predominantly White clinic-based study with a Black-and-White community-based study found that associations among dementia risk factors, cognition, and brain imaging differed between the populations. The NIA's diversity research summary warns against assuming one study population represents everyone.
Questions readers can use
A useful dementia news report should let readers identify the population studied without digging through a technical paper. When evaluating a headline, ask: For treatment decisions, compare those answers with the individual patient's diagnosis, stage, test results, other conditions, and medications.
A clinician can help determine whether the study population resembles that patient closely enough for the evidence to inform care. A cautious report should not dismiss a study because its population was narrow. It should state the boundary plainly: strong evidence for the enrolled group may still leave an important unanswered question for everyone outside it.
- What diagnosis and disease stage did participants have?
- Were amyloid, tau, cognitive-score, or imaging requirements used?
- Which health conditions, medicines, ages, or practical barriers caused exclusion?
- How many participants came from each racial, ethnic, and sex group?
- Were subgroup results actually tested, or were the groups too small?
